A Phase IB Study of CX-5461 in People with Advanced Pancreatic Cancer Containing Certain Genetic Mutations


Full Title

Phase Ib Expansion Study of CX-5461 in Patients with Solid Tumours and BRCA2 and/or PALB2 Mutation


The purpose of this study is to assess two different doses of the investigational drug CX-5461 that can be given safely to people with metastatic pancreatic cancer that contains a mutation in the BRCA1, BRCA2, or PALB2 genes, or a genetic change called a homologous recombination deficiency (HRD)-associated mutation. These mutations can cause cells to become abnormal, leading to cancer growth and spread.

CX-5461 interrupts the process of cancer cell growth, causing cancer cells to die. It is given intravenously (by vein).


To be eligible for this study, patients must meet several requirements, including:

  • Participants must have advanced pancreatic adenocarcinoma that contains a mutation in the BRCA1, BRCA2, or PALB2 genes or an HRD-associated mutation.
  • The serious side effects of previous treatments must go away before CX-5461 is given.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

For more information and to ask about eligibility for this study, please contact the office of Dr. Kenneth Yu at 646-888-4188.